. 2021 Jul 7;148(13):1545–1553. doi: 10.1017/S0031182021001128

Table 4.

Effect of treatment during the chronic stage of infection¹ on parasite muscle burden

	CBi/L		CBi+
	Males	Females	Males	Females
Treatment	Variable: rLL²^,³
Control	240 ± 45.5^a	173 ± 75.5^a	998 ± 74.8^a	752 ± 157.9^a
ABZ	268 ± 71.6^a	283 ± 94.9^a	1084 ± 201.8^a	794 ± 144.9^a
S4A	266 ± 46.7^a	172 ± 45.7^a	1177 ± 154.8^a	662 ± 197.0^a
S10A	338 ± 57.6^a	130 ± 26.1^a	1172 ± 287.8^a	883 ± 210.9^a
	Variable: Proportion of dead T. spiralis muscle larvae (%)⁴^,⁵
Control	20 (8–29)^a	9 (0–25)^a	24 (14–33)^a	7 (4–14)^a
ABZ	28 (0–37)^a	37 (0–68)^a	30 (15–60)^a	7 (5–21)^a
S4A	29 (14–37)^a	33 (0–96)^a	38 (7–93)^a	13 (6–20)^a
S10A	64 (18–88)^b	50 (6–100)^a	54 (13–74)^a	12 (5–22)^a

Differences among treatments within genotype and sex were evaluated with the nonparametric Kruskal–Wallis test followed by Dunn's test for between-groups comparison.

Differences among groups, within genotype and sex, were evaluated with the non-parametric Kruskal–Wallis test, using Dunn's test for comparisons between groups.

For each variable, within column, groups not sharing the same superscript differ significantly (P < 0.05).

Mice were treated on days 27, 28 and 29 p-i and were sacrificed on day 37 p-i.

rLL: relative larval load, total number of muscle encysted larvae per g of fresh tissue.

Mean ± s.e.m.

⁴

Percentage of dead muscle encysted larvae.

⁵

Median (range).